Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

@article{Kreitman2000CytotoxicAO,
  title={Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.},
  author={Robert J. Kreitman and Inger M. K. Margulies and Maryalice Stetler-Stevenson and Qing Cheng Wang and David J P Fitzgerald and Ira Pastan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2000},
  volume={6 4},
  pages={1476-87}
}
Chemical conjugates of anti-CD22 monoclonal antibodies and toxins have been used to treat CD22+ hematological malignancies. A new anti-CD22 recombinant immunotoxin RFB4(dsFv)-PE38, composed of the Fv portion of the monoclonal antibody RFB4 fused to a truncated form of Pseudomonas exotoxin A, is being developed to target CD22+ tumor cells. To explore the potential clinical utility of this recombinant toxin in treating patients with B-cell malignancies, the fresh cells of patients were incubated… CONTINUE READING
36 Extracted Citations
37 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 36 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 37 references

Similar Papers

Loading similar papers…